[Prevalence of phzMand pvdAvirulence genes in pseudomonas aeruginosa isolated from Infectious disease ward patients]

Background and Aim: Pseudomonas aeruginosa is one of the most important causes of nosocomial infections and septicemia in patients with burn and cystic fibrosis. It is found in water and wet soil. PhzM and PvdA are virulence genes involved in the production of two iron carriers, pyoverdine and pyocyanin. Considering the importance of virulence genes in the bacteria, determination of the frequency of these genes in clinical and environmental samples has shown an increasing trend. The aim of this study was to investigate the prevalence of virulence genes in pseudomonas aeruginosa isolated from infected patients

Material and Method: Clinical samples were obtained from the patients referring to Kermanshah hospitals. After isolation and identification of Pseudomonas aeruginosa strains, DNA extraction was performed by Sina Kit gene and the presence of genes evaluated by PCR. Data were analyzed by using SPSS v20 software

Results: Among 106 strains, 34 [32.07%] and 47 [44.33%] strains were positive for pvdA and phzM genes, respectively. The logistic regression analysis revealed significant correlations between the presence of pvda gene and samples of urine [p<0.001], blood [p= 0.002], wound [p=0.004] and lung secretion [p=0.013]. Foremore, there was no relationship between the presence of phzM gene and the above mentioned samples

Conclusion: We found moderate prevalence rates for phzMand pvdAvirulence genes in pseudomonas aeruginosa isolated from Kermanshah hospitals

Sequence variants of BRCA1 and BRCA2 genes in four Iranian families with breast and ovarian cancer

BRCA1 and BRCA2 genes have been recognized to be responsible for 20-30% of hereditary breast cancers and approximately 50% of familial breast and ovarian cancers. Therefore, the demand for BRCA1 and BRCA2 mutation screening is rapidly increasing as their identification will affect medical management of people at increased risk. Because of high costs involved in analysis of BRCA1 and 2 genes, contribution of different mutation types in BRCA1 and 2 and not knowing who should be tested has hampered wide spread use of molecular testing of high -risk families. There is a need to identify the genes and types of mutations involved in breast or ovarian cancers at different age of onsets and polymorphism and polymorphic variations in our population. Twenty-seven patients with either early onset breast cancer [at age